Aspirin resistance
This presentation is the property of its rightful owner.
Sponsored Links
1 / 30

Aspirin Resistance PowerPoint PPT Presentation

  • Uploaded on
  • Presentation posted in: General

Aspirin Resistance. Clinical Questions. How do we define aspirin resistance? Is this concept clinically relevant? Why aren’t we testing for it?. Aspirin Basics. Antithrombotic Trialists’ Collaboration

Download Presentation

Aspirin Resistance

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript

Aspirin resistance

Aspirin Resistance

Clinical questions

Clinical Questions

  • How do we define aspirin resistance?

  • Is this concept clinically relevant?

  • Why aren’t we testing for it?

Aspirin basics

Aspirin Basics

  • Antithrombotic Trialists’ Collaboration

    • Major meta-analysis reporting 25% reduction in significant vascular events as secondary prevention

    • Prevents at least 10-20 fatal and nonfatal vascular events for every 1000 patients treated for one year.

  • American Heart Association recommends prophylaxis for: 10yr risk of CHD >10%

  • Pharmacology

    • Consistent absorption via passive diffusion in GI tract with peak plasma levels in 30min

    • Enteric coated peak in 3-4 hours with variable bioavailability

Platelet basics

Platelet Basics

Wide acceptance that platelet activity plays a major role in atherothrombosis

Adhesion: Platelet membrane receptors bind to endothelium and subendothelium at sites of damage

Activation: Transmembrane signaling increases surface receptors, granule release, and exposure of membrane phospholipid

Aggregation: Procoagulant surface of the membrane serves as basis for coagulation cascade, amplification of platelet response, and production of fibrin.

Aspirin inhibition of platelets

Aspirin Inhibition of Platelets

Aspirin inhibits platelet cyclooxygenase (COX)-1 thereby preventing formation of thromboxane A2 (TxA2), a potent aggregating and vasocontrictor agent.

  • Acetylation serine 529 of COX-1

  • Platelets – anucleate and unable to regenerate COX-1

    • Platelet lifespan 7-10 days

    • Maturation time from megakaryocytes: 4 days

Nsaid mechanism

NSAID Mechanism

Definition of aspirin resistance

Definition of “Aspirin Resistance”

  • Clinical failure of prevention

  • Biochemical resistance

  • Laboratory Phenomenon


  • Patient just doesn’t

    want to take it.

Clinical aspirin resistance

Clinical “Aspirin Resistance”

  • Perhaps more appropriate term would be “treatment failure”

  • Probabilities Game

  • Failure is to be expected in the treatment/prevention of any multi-factorial disease process

Theories of biochemical resistance

Theories of Biochemical Resistance

  • Endothelial cells recover COX-1 activity shortly after aspirin exposure

  • Role of COX-2 in thrombotic process

  • Thromboxane-independent methods of platelet activation

  • Genetic polymorphisms

    • GP IIb-IIIa receptor

    • Platelet alloantigen 2 (PlA2)

Laboratory definition

Laboratory Definition

  • Bleeding time

  • Aggregometry

  • Platelet function analyzer (PFA-100)

  • Platelet Release Products

  • VerifyNow Aspirin

  • Platelet Membrane Expression

Bleeding time

Should not be used

Low Sensitivity


Poorly reproducible

Multiple Variables

Platelet function

Platelet count

Plasma factors

Red Blood Cells

Skin trophism

Bleeding Time



Light Transmission Aggregometry

  • Measures light transmission through a platelet suspension in response to agonist (arachodonic acid or ADP)

  • Reports: % residual platelet function

  • Clinical association with vascular events

  • Historic Reference Standard

    • time-consuming and user-dependent

    • limited availability and requires rapid analysis

    • lack of standardization



Whole Blood Aggegrometry

  • Measures electrical impedance between two electrodes immersed in whole blood 5min after addition of a platelet agonist

  • Reports: impedance in Ω

  • Easy, sensitive, reproducible

    • Large sample of blood required

    • Long preparation time

    • Expensive

Platelet function analyzer 100

Reports: closure time (<193s)

No association with vascular events

Point-of-Care test

Must test within 4hrs of blood collection

Dependent on hematocrit and vWF

Anticoagulated blood is aspirated through a capillary and a 150μm aperture coated with collagen and ADP or epinephrine. Measures time needed until blood flow interruption is recorded.

Platelet Function Analyzer-100

Platelet release products

Platelet Release Products

Serum TXA2

Urinary 11-dehydrothromboxane B2

  • Directly dependent on aspirin’s effect on COX-1 inhibition

  • Simple and correlated with clinical events

    • Indirect measurement

    • Not specific to platelets

    • Urinary test dependent on renal function

Verfiynow aspirin

Turbidometric-based optical system that measures agglutination of fibrinogen-coated beads by platelets stimulated in citrated whole blood.

Reports: Aspirin Reaction Units

Clinical association with vascular events

Point-of-care test

Major limitation relates to the diagnostic criteria set for definition of aspirin resistance

Compared to optical aggregometry with epinephrine after one 325mg dose of aspirin

VerfiyNow Aspirin

Platelet membrane expression

Platelet bound P-selectin

Soluble plasma P-selectin

Platelet-leukocyte aggregates

Platelet-derived microparticles

Flow cytometry allows for the evaluation of platelet reactivity and in vivo activation. However, these techniques require sophisticated and expensive instruments.

Platelet Membrane Expression

Aspirin resistance

A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.

Marie Lordkipanidze, Chantal Pharand, Erick Shampaert, Jacques Turgeon, Donald Palisaitis, and Jean G. Diodati.

European Heart Journal in June 2007

Study design

Study Design

  • 201 patients with stable CAD on daily aspirin therapy (>80mg)

    • Consecutive patients diagnosed with CAD

    • Montreal, Canada

    • Sample collection: morning urine and blood

  • Exclusions:

    • ACS or revascularization within 6 months

    • Concurrent use of NSAIDs, clopidogrel, dipyridamole, warfarin, acenocoumarol

    • Major surgery within 1 month of enrollment

    • Thrombocytopenia, Hct <25%

    • Dialysis

Platelet function tests

Platelet Function Tests

  • LTA with arachidonic acid

  • LTA after adenosine diphosphate

  • Whole blood aggregometry

  • PFA-100

  • VerifyNow Aspirin

  • Urinary 11-dehydrothrombaxane B2

Patient data

Patient Data

  • 155 Male (71%)

  • Mean Age: 66.5 ± 10.4

  • All with aspirin ≥ 1 month

    • 80mg – 110 patients

    • 81mg – 10 patients

    • 162.5mg – 1 patient

    • 325mg – 79 patients

    • 1300mg – 1 patient



κ StatisticAgreement

0 - 0.2Slight

0.2 - 0.4Fair

0.4 - 0.6Moderate

0.6 - 0.8Substantial

Prevalence of resistance

Prevalence of Resistance



  • Overall, poor correlation between different platelet function tests

  • “Aspirin resistance” based on arbitrary, clinically non-validated cut-off values.

    “We believe the non-standardized use of these assays and the absence of a formal definition explains much of the disparity reported in the literature in regards to the prevalance of aspirin resistance.”

  • Perhaps it is more important to determine cut-off values with the intent of predicting clinical outcomes instead of focusing on a “gold standard” test.

Clinical confounders

Drug Interactions:


may occupy nearby catalytic site

Block access of aspirin to serine 529

Ibuprofen, Indomethacin


ACE Inhibitors?

Comorbid Conditions


prostaglandin F2-like compounds

Produced from arachidonic acid in a non-COX process

Amplify platelet response




Unstable Angina

Clinical Confounders

Variable aspirin response

Variable Aspirin Response

  • Most studies have not evaluated aspirin resistance over time

  • Cohort study out of the University of Chicago published in 1994

    • Secondary prevention in 306 patients with history of ischemic stroke

    • Repeated assessments of aspirin resistance over a 6 month interval

    • Light Transmission Aggregometry

    • 32.7% of patients did not maintain complete inhibition with repeated testing

  • Reassessment of fixed-dose regimens?

Patient compliance

Patient Compliance

No laboratory testing to monitor for clinical adherence

  • Schwartz, et al. studied tested 190 patients using LTA and found 9% resistance

    • Repeat testing after directly observed therapy in all 9%

    • Nonresponders  responders

  • Tantry, et al. studied 223 patients with CHD

    • All but 7 patients had aspirin response via LTA

    • Those 7 patients were interviewed again and admitted to noncompliance

Working group on aspirin resistance in 2005

Working Group on Aspirin Resistance in 2005

“Other than in research trials, it is not currently appropriate to test for aspirin ‘resistance’ in patients or change therapy based on these tests.”



  • “Aspirin Resistance,” from biochemical and lab perspective, probably has clinical relevance

  • There continues to be significant investigation and discovery regarding aspirin therapy

  • Clinical application is on the distant horizon.

  • Consider alternatives to NSAIDs

  • Focus on patient compliance

    • seek to dispel myths

    • assess for and control side effects.



  • Airee, et al. Aspirin resistance: disparities and clinical implications. Pharmacotherapy 2008; 28(9): 999-1018.

  • Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.

  • Cattaneo, M. Resistanc to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost 2007; 5 (Suppl 1): 230-7.

  • Christiaens, et al. Major clinical vascular events and aspirin-resistance status determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study. Blood Coag and Fib 2008. 19(3): 235-9.

  • Gasparyan, et al. The role of aspirin in cardiovascular prevention. J Am Coll Cardiol 2008. 51; 19: 1829-43.

  • Gum, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41(6): 961-5.

  • Helgason, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994. 25: 2331-2336

  • Lordkipanidze, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Euro Heart J 2007; 28(14): 1673-5.

  • MacDonald, et al. Effect of ibuprofen on the cardioprotective effect of aspirin. Lancet 2003. 15; 361(9357): 573-4.

  • Michelson, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3: 1309-11.

  • Patrono, et al. Low-dose aspirin for prevention of atherothrombosis. N Engl J Med 2005. 353; 22: 2373-83.

  • Sanderson, et al. Narrative review: aspirin resistance and its clinical implications. Annals of Int Med 2005. 142; 5: 370-80.

  • Viola et al. Aspirin resistance: is this term meaningful? Curr Opin Hematol 2006. 13: 331-336.

  • Login